Morning Overview on MSN

Experimental prostate cancer drug shrinks tumors in early clinical trial

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...
Targeted Oncology

Aglatimagene Besadenovec Shows Durable Survival in ICI-Refractory NSCLC

The FDA has previously granted fast track designation to aglatimagene plus valacyclovir in combination with ICI therapy for ...

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air ...
Morningstar

Williams Cancer Institute Presents Data on Combined Pulsed Electrical Field Ablation and Intratumoral Immunotherapy at SITC 2025

BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...
Seeking Alpha

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel ...
ascopubs.org

Phase I/II Study of Intratumoral Ad/Purine Nucleoside Phosphorylase (Gedeptin) With Fludarabine Phosphate in Patients With Recurrent Head and Neck Cancer

Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311 Ad/PNP (Gedeptin) is a ...
Seeking Alpha

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery ...

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety The manuscript is ...